198 related articles for article (PubMed ID: 7523702)
41. [The role of prostate specific antigen in diagnosis of localized adenocarcinoma of the prostate. Nara Uro-Oncology Research Group].
Hirao Y; Ozono S; Kagebayashi Y; Yoshi M; Tani Y; Uemura H; Momose H; Okajima E
Hinyokika Kiyo; 1996 Oct; 42(10):795-804. PubMed ID: 8951478
[TBL] [Abstract][Full Text] [Related]
42. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a USA perspective--identifying men at diagnosis who are at high risk of prostate cancer death after surgery or radiation therapy.
D'Amico A
BJU Int; 2007 Jan; 99 Suppl 1():13-6; discussion 17-8. PubMed ID: 17229162
[TBL] [Abstract][Full Text] [Related]
43. PSA testing: an evolving relationship with prostate cancer screening.
Constantinou J; Feneley MR
Prostate Cancer Prostatic Dis; 2006; 9(1):6-13. PubMed ID: 16314892
[TBL] [Abstract][Full Text] [Related]
44. Prognostic value of serum markers for prostate cancer.
Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
[TBL] [Abstract][Full Text] [Related]
45. The role of PSA and percent free PSA for staging and prognosis prediction in clinically localized prostate cancer.
Pannek J; Partin AW
Semin Urol Oncol; 1998 Aug; 16(3):100-5. PubMed ID: 9741413
[TBL] [Abstract][Full Text] [Related]
46. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer.
Partin AW; Yoo J; Carter HB; Pearson JD; Chan DW; Epstein JI; Walsh PC
J Urol; 1993 Jul; 150(1):110-4. PubMed ID: 7685418
[TBL] [Abstract][Full Text] [Related]
47. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
Sheridan T; Herawi M; Epstein JI; Illei PB
Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
[TBL] [Abstract][Full Text] [Related]
48. Prostate-specific antigen: biochemistry, analytical methods, and clinical application.
Armbruster DA
Clin Chem; 1993 Feb; 39(2):181-95. PubMed ID: 7679336
[TBL] [Abstract][Full Text] [Related]
49. Prostate-specific antigen in screening of prostate cancer.
Chu TM
J Clin Lab Anal; 1994; 8(5):323-6. PubMed ID: 7528795
[TBL] [Abstract][Full Text] [Related]
50. Combined nested RT-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in prostate cancer patients: correlation with pathological stage.
Grasso YZ; Gupta MK; Levin HS; Zippe CD; Klein EA
Cancer Res; 1998 Apr; 58(7):1456-9. PubMed ID: 9537248
[TBL] [Abstract][Full Text] [Related]
51. Prostate specific antigen density of the transition zone for predicting pathological stage of localized prostate cancer in patients with serum prostate specific antigen less than 10 ng./ml.
Zlotta AR; Djavan B; Petein M; Susani M; Marberger M; Schulman CC
J Urol; 1998 Dec; 160(6 Pt 1):2089-95. PubMed ID: 9817330
[TBL] [Abstract][Full Text] [Related]
52. [Advanced prostate cancer with normal serum prostate-specific antigen values].
Komura T; Yamagiwa K; Ogura H; Kohjimoto Y; Ohkawa T; Inagaki T; Ebisuno S; Senzaki A
Hinyokika Kiyo; 1998 May; 44(5):303-6. PubMed ID: 9656099
[TBL] [Abstract][Full Text] [Related]
53. Clinical usefulness of free PSA in early detection of prostate cancer.
Luboldt HJ; Swoboda A; Börgermann C; Fornara P; Rübben H;
Onkologie; 2001 Feb; 24(1):33-7. PubMed ID: 11441278
[TBL] [Abstract][Full Text] [Related]
54. [Serum markers for early detection and staging of prostate cancer. Status report on current and future markers].
Haese A; Graefen M; Palisaar J; Huland E; Huland H
Urologe A; 2003 Sep; 42(9):1172-87. PubMed ID: 14504750
[TBL] [Abstract][Full Text] [Related]
55. Optimized strategy for detection of early stage, curable prostate cancer: role of prescreening with prostate-specific antigen.
Labrie F; Dupont A; Suburu R; Cusan L; Gomez JL; Koutsilieris M; Diamond P; Emond J; Lemay M; Candas B
Clin Invest Med; 1993 Dec; 16(6):425-39. PubMed ID: 7516831
[TBL] [Abstract][Full Text] [Related]
56. Prediction of pathological stage in patients with clinical stage T1c prostate cancer: the new challenge.
Veltri RW; Miller MC; Mangold LA; O'Dowd GJ; Epstein JI; Partin AW
J Urol; 2002 Jul; 168(1):100-4. PubMed ID: 12050500
[TBL] [Abstract][Full Text] [Related]
57. Influence of patient age on the serum PSA concentration. An important clinical observation.
Oesterling JE; Cooner WH; Jacobsen SJ; Guess HA; Lieber MM
Urol Clin North Am; 1993 Nov; 20(4):671-80. PubMed ID: 7505975
[TBL] [Abstract][Full Text] [Related]
58. Early detection of prostate cancer with low PSA cut-off values leads to significant stage migration in radical prostatectomy specimens.
Berger AP; Spranger R; Kofler K; Steiner H; Bartsch G; Horninger W
Prostate; 2003 Oct; 57(2):93-8. PubMed ID: 12949932
[TBL] [Abstract][Full Text] [Related]
59. Prospective detection of clinically relevant prostate cancer in the prostate specific antigen range 1 to 3 ng./ml. combined with free-to-total ratio 20% or less: the Aarau experience.
Recker F; Kwiatkowski MK; Huber A; Stamm B; Lehmann K; Tscholl R
J Urol; 2001 Sep; 166(3):851-5. PubMed ID: 11490232
[TBL] [Abstract][Full Text] [Related]
60. Prostate-specific antigen velocity and prostate cancer gleason grade and stage.
Pinsky PF; Andriole G; Crawford ED; Chia D; Kramer BS; Grubb R; Greenlee R; Gohagan JK
Cancer; 2007 Apr; 109(8):1689-95. PubMed ID: 17330856
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
